Innate Pharma 9M Revenue €3.4M Vs €2.3M YoY, Cash €96.8M; CFO Frédéric Lombard To Step Down December 31
Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person eventLacutamab, partnered with Sobi, progressing toward first patient dosing in the
Innate Pharma earned more money this year than last year. The company still has plenty of cash to keep working on medicines.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.